Obstructive sleep apnea (OSA) and the metabolic syndrome have a strong association with each other owing to their common feature of obesity, but an association independent of obesity has been ...

Double-headed arrow (between “Obstructive sleep apnea syndrome” and “Obesity”): This indicates ... corresponds to a 32% rise in the apnea-hypopnea index (AHI), a key measure of OSA severity.

Double-headed arrow (between “Obstructive sleep apnea syndrome” and “Obesity”): This indicates a bidirectional relationship between Obstructive sleep apnea syndrome and obesity.

Weight loss could help improve obstructive sleep apnea in patients ... extend to individuals with obesity who are not diabetic Changes in the apnea–hypopnea–index (AHI) were assessed by ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

New research highlights that severe obstructive sleep apnea (OSA) independently predicts elevated C-reactive protein (CRP) ...

Obesity significantly increases the risk of obstructive sleep apnea (OSA) due to fat accumulation in the neck and abdominal areas, leading to airway collapse and breathing disruptions during sleep.

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients ...

What Is Obstructive Sleep Apnea? Obstructive sleep apnea is when something blocks part or all of your upper airway while you sleep. This means your diaphragm, a muscle that helps you breathe in ...

Auto-titrating continuous positive airway pressure, or AutoCPAP therapy, is useful for the treatment of obstructive ... sleep apnea and may improve treatment of obesity-hypoventilation syndrome ...

INDIANAPOLIS (dpa-AFX) - The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea or OSA in adults with obesity ...